Immutep to halt Phase III lung cancer trial after interim futility review
Immutep (NASDAQ:IMMP) announced on March 13, 2026, that it will shut down its Phase III TACTI-004 clinical trial evaluating eftilagimod alpha ("efti") in combination with anti-PD-1 therapy for first-line non-small cell lung cancer (NSCLC).

_1359411_640x360_2491937347892-640x360.webp&w=1200&q=75)

_1359393_640x360_2491938883535-640x360.webp&w=1200&q=75)

-640x360.jpg&w=1200&q=75)
-640x360.jpg&w=1200&q=75)













